This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Amicus Therapeutics Inc. (therapies for rare metabolic conditions) netted $282mm in its follow-on public offering of 19.35mm common shares at $15.50. The company will use some of the proceeds for global commercialization of migalastat for Fabry's disease, to invest in manufacturing capabilities for its Phase II Pompe disease candidate ATB200, and for additional R&D and commercial activities.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?